Mestastop Solutions builds a cancer metastasis-focused platform that uses wet-lab biology and predictive analytics to identify and distinguish unique properties of metastasis. Its proprietary platforms include METAssay, METSCAN, and METVivo, with METSCAN positioned as an AI-based tool that characterizes cancer cells using patient data and assay panels. The company plans to scale METSCAN and run proof-of-concept animal model studies to validate approaches for cancer drug discovery and drug repurposing. Mestastop was founded in 2018 and is led by founders Dr. Arnab Roy Chowdhury and Dr. Debabani Roy Chowdhury, supported by a cross-functional team trained in discovery, diagnostics, and AI and by state-of-the-art infrastructure. The company raised Rs 1.3 crore in a seed round in October 2021 to fund platform scaling and PoC studies.

Total raised

$0M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2021